Breadcrumb trail

Need Help or want to give your feedback?

Whether you’re having trouble with your account, or would like to make a suggestion, Canadian Blood Services offers you quick and convenient options to troubleshoot or get in touch. Contact us via live chat, consult our FAQ, send an email, or give us a call at 1 888 2 DONATE (1-888-236-6283).

Goldman, Mindy

Back To Our Investigators

Mailing Address:

Canadian Blood Services
1800 Alta Vista Dr.
Ottawa, ON, K1G 4J5


University of Ottawa
Google Scholar

Medical Director
Donor and Clinical Services
Canadian Blood Services

Adjunct Professor
Department of Pathology and Laboratory MedicineFaculty of Medicine, University of Ottawa

Donor screening and donor criteria

Volunteer donors are the backbone of the blood system in Canada. Our research explores the potential impact of changes to donor criteria and donor screening policies, both on blood safety and on donor safety and impact on the blood supply.

Why is this important?

A better understanding of our donor base is vital to protecting donors’ health and safety and ensuring a safe and adequate blood supply.  Ideally, donor criteria should be evidence based and evolve with new scientific findings.

While ensuring a sufficient and safe blood supply is important, this should not be achieved at the detriment of donor health.  Together with Dr. Sheila O’Brien, head of our Epidemiology group, we are investigating iron deficiency in Canadian donors, a major focus of investigation by blood operators worldwide.  We have found that many of our regular donors have low or absent iron stores, and will be changing our criteria for blood donation based on our findings.  We are also evaluating the feasibility of performing iron (ferritin) testing on a subset of donors at particularly high risk for iron deficiency.

Together with our Epidemiology group, we perform large, anonymous donor surveys to provide information on donor motivation, tolerance of donation, and compliance with criteria.  We have used this survey to explore compliance with changes in donor criteria, such as the recent change from an indefinite to a 5 year deferral for men who have sex with men.  We also collaborate with other international blood operators to ensure our policies and procedures are in line with industry best practices.

Selected Publications:

  1. Goldman M, Land K, Robillard P, Wiersum-Osselton J.  Development of standard definitions for surveillance of complications related to blood donation.  Vox Sang 2016 February;110 (2):185-8.
  2. O'Brien SF, Osmond L, Choquet K, Yi QL, Goldman M. Donor attention to reading materials. Vox Sang. 2015 Nov;109(4):336-42.
  3. Goldman M, Uzicanin S, Scalia V, O'Brien SF: Iron Deficiency in Canadian Blood Donors.  Transfusion 2014; 54:775-779.
  4. Goldman M: ResearchUnit: Protecting our life blood: iron deficiency in Canadian donors. 2014.
  5. Germain M, Robillard P, Delage G, Goldman M: Allowing blood donation from men who had sex with men more than 5 years ago: a model to evaluate the impact on transfusion safety in Canada. Vox Sang 2014; 106:372-375.



Canadian Blood Services performs prenatal testing for the western provinces, and has reference laboratories to assist hospitals in the investigation of difficult immunohematology cases.

Why is this important?

We have investigated the use of genotyping in the prenatal, diagnostic, and donor setting.  We have developed an algorithm for RhD genotyping in prenatal patients with a serologic weak D phenotype to avoid unnecessary administration of anti-D in a subset of pregnant women.  We have also evaluated the frequency of various antibodies in prenatal patients, including the importance of antibodies to anti-Kell.

Selected publications:

  1. Goldman M, Nogues N, Castilho LM.  An overview of the Progenika ID Core XT: an automated genotyping platform based on a fluidic microarray system.  Immunohematology 2015;31(2):62-68.
  2. Goldman M, Cote J, Hannon J, Clarke G et al.  RhD genotyping for prenatal patients with a serologic weak D phenotype.  Transfus Med Rev 2015;29:276-277.
  3. Goldman M, Lane D, Webert K, Fallis W.  The prevalence of anti-K in Canadian prenatal patients.  Transfusion 2015;55:1489-1491.


Leadership Roles:

2015 - ongoing
  • AABB Donor Health and Safety Committee
  • AABB Hemovigilance Committee
  • AABB Bacterial task force
  • ISBT Haemovigilance Committee
  • CSTM annual meeting scientific planning committee
  • Alliance of Blood Operators medical group
  • Editorial Board, Transfusion


  • MD, University of Montreal

  • Residency in Internal Medicine, McGill University

  • Residency in Hematology and Transfusion medicine, McMaster University